John Armitage
Egerton Capital
John Armitage AbbVie Inc stake
total: 222
Egerton Capital ABBV trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2014 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2015 Q1
According to 2026 Q2 report, John Armitage doesn't hold any AbbVie Inc (ABBV) shares. To date, the estimated cost basis is nearly $65.44 for "buy" trades and estimated average "sell" price is $65.44. Egerton Capital first purchased ABBV in 2014 Q4, initially acquiring about 3.90M shares. Since the initial investment in AbbVie Inc (ABBV), Egerton Capital has made 1 more transaction.
When did John Armitage sell AbbVie Inc (ABBV)?
John Armitage sold off the entire AbbVie Inc (ABBV) position in 2015 Q1.
When did John Armitage buy AbbVie Inc (ABBV)?
John Armitage first invested in AbbVie Inc (ABBV) in 2014 Q4 at the reported quarter-end price of $65.44 per share.
What's the cost basis of Egerton Capital's ABBV stake?
The estimated cost basis for AbbVie Inc (ABBV) stake is around $65.44 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $65.44
- Weighted AVG sell price:
- $65.44
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.